길랭 바레 증후군(GBS) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Guillain-Barre Syndrome (GBS) Market size is expected to reach USD 1.41 Billion in 2034 from USD 0.79 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Guillain-Barre Syndrome (GBS) Market is growing as awareness of rare neurological disorders increases and diagnostic capabilities improve. Guillain-Barre syndrome is a serious autoimmune condition that affects the peripheral nervous system and requires timely medical intervention. Rising healthcare spending and advancements in neurology research have contributed to the growing availability of effective treatment options, thereby supporting the market's expansion.

Key drivers of the GBS market include the increasing incidence of autoimmune diseases and infections that may trigger the syndrome. Improved healthcare infrastructure and early diagnosis have enabled better disease management. Additionally, pharmaceutical companies and research institutions are investing in clinical trials to develop more effective therapies and supportive treatments, which is expected to boost the overall treatment landscape.

In the future, the market is anticipated to expand with advancements in immunotherapy and personalized medicine. Increasing focus on rare disease research, along with government initiatives supporting neurological disorder treatment, will likely improve patient outcomes. As medical technologies evolve and awareness continues to grow, the Guillain-Barre syndrome market is expected to see steady progress worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange
• Others

By Type

• Acute inflammatory demyelinating polyneuropathy (AIDP)
• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• Miller fisher syndrome (MFS)
• Acute motor axonal neuropathy (AMAN)
• Others

By Route of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Biogen Inc, Cadila Healthcare Limited, CSL Limited, F HoffmannLa Roche Ltd, GlaxoSmithKline plc, Grifols, SA, LGM Pharma, Merck Co Inc, Octapharma AG, Pfizer Inc, Takeda Pharmaceutical Company Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Intravenous Immunoglobulin (IVIG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Plasma Exchange Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Acute inflammatory demyelinating polyneuropathy (AIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Miller fisher syndrome (MFS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Acute motor axonal neuropathy (AMAN) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapeutics
  • 8.2.2 By Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapeutics
  • 8.3.2 By Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapeutics
  • 8.4.2 By Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapeutics
  • 8.5.2 By Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapeutics
  • 8.6.2 By Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Biogen Inc
  • 10.2.3 Cadila Healthcare Limited
  • 10.2.4 CSL Limited
  • 10.2.5 F. Hoffmann-La Roche Ltd
  • 10.2.6 GlaxoSmithKline Plc
  • 10.2.7 Grifols
  • 10.2.8 S.A
  • 10.2.9 LGM Pharma
  • 10.2.10 Merck & Co. Inc
  • 10.2.11 Octapharma AG
  • 10.2.12 Pfizer Inc
  • 10.2.13 Takeda Pharmaceutical Company Limited